RE:RE:Took some Several items regarding the 4 modules, financing, etc.
First, I believe module 1 was 100% paid for the RegenX. It is my understanding that once commercialization is proven with module 1, then Davis will reimburse for their 45% share of module 1.
Second, I believe it is their hope/intent to build-out modules 2-4 at the same time. This will require some form of financing. Greg has indicated that it would be a more traditional financing, which I assume indicates debt as opposed to share dilution. This should be 45% Davis.
Their hope/intent to build-out the other 3 modules is bullish in my opinion. To me, it indicates they are quite optimistic of revenue/profit given the data they have available to them.